SIP Customs announced a set of new measures on Sept 11 to bolster open innovation across the biomedical industry chain for high-quality development.
SIP Customs instituted 10 measures last year with the aim of accelerating the development of biomedical industry. Over the past one year, these measures have shown good effect, and several of them have been rolled out across Suzhou and even Jiangsu province.
“We have upgraded these measures to simplify the regulatory process to the largest extent, achieve the fastest speed in customs clearance and help strengthen the competitiveness of biotech companies,” said Wu Lin, deputy director of SIP Customs.
In addition to the unveiling of the new measures, SIP Customs explained to biotech companies a series of policies on risk classification and assessment for special goods, supervision for imported and exported biological materials, customs clearance of pharmaceuticals and other issues.
September 11, 2025
